Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Ann Oncol, Volume 30, Issue 2, 10 December 2018, Pages 290–296, https://doi.org/10.1093/annonc/mdy512 The content of this slide may be subject to copyright: please see the slide notes for details.
Figure 2. Prognostic performance of the presence of co-occurring pathogenic alterations in (A) entire cohort, (B) ... Figure 2. Prognostic performance of the presence of co-occurring pathogenic alterations in (A) entire cohort, (B) subgroup of patients with actionable alterations and (C) subgroup of patients with non-actionable alterations. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Ann Oncol, Volume 30, Issue 2, 10 December 2018, Pages 290–296, https://doi.org/10.1093/annonc/mdy512 The content of this slide may be subject to copyright: please see the slide notes for details.